Consistent with these findings, aldometanib significantly enhanced the sensitivity of HCC to immunotherapy, resulting in more pronounced death of HCC cells when combined with the anti-PD-1 antibody (Fig. 4o; Supplementary information, Fig. S12e). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.